![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EUROPEAN UNION'S CHMP ADOPTS POSITIVE OPINION FOR SUBOXONE (BUPRENORPHINE/NALOXONE) FOR TREATMENT OF OPIOID DEPENDENCE
EUROPEAN UNION'S CHMP ADOPTS POSITIVE OPINION FOR SUBOXONE (BUPRENORPHINE/NALOXONE) FOR TREATMENT OF OPIOID DEPENDENCE
Schering-Plough Corporation announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has granted a positive opinion recommending approval of SUBOXONE (buprenorphine hydrochloride/naloxone hydrochloride) Sublingual Tablets for the substitution treatment of opioid dependence, within a framework of medical, social and psychological treatment.
Pipeline Review (http://www.pipelinereview.com/joomla/content/view/5498/109/)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct